drug dapaglifozin until more trial data become available. Talha Khan Burki reports. Last month, US regulators informed AstraZeneca and Bristol-Myers Squibb that they are not yet able to approve dapagliflozin, an oral antidiabetic drug on which the two companies

indication cannot infringe under § 271(e)(2)(A). This holding is virtually identical to the Warner-Lambert decision. AstraZeneca attempted to exploit the main difference between the two cases, namely that the NDA holder in Warner-Lambert had not obtained approval

Plc (AZN) lost a U.S. appeals court bid to protect its best-selling drug, Crestor, from generic competition until as late as 2021. A judge was correct to dismiss AstraZeneca’s lawsuits against Teva Pharmaceutical Industries Ltd. (TEVA) and other generic- drug

The company has not yet officially disclosed where the jobs will go and from which site. David Brennan, chief executive at AstraZeneca, said: “While the further expected losses of market exclusivity make for a challenging 2012 outlook, we remain committed

2/8/2012 1:42:16 PM The Food and Drug Administration is warning consumers today that certain stomach acid drugs may increase the risk of a serious intestinal bacteria infection. The drugs, including Nexium, Prilosec, Prevacid, Zegerid and others, fall into

- Health regulators said ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of clostridium difficile-associated diarrhea (CDAD). Clostridium difficile is a bacterium that can cause colitis and other intestinal conditions. The

(NYSE: AZN) reports it broadened the income eligibility for its AZ&Me Prescription Savings programs to enable more people to qualify for free medicines. The new annual household income eligibility levels are $35,000 for individuals, $48,000 for couples, $60,000

layoffs along with a stock buyback - let's think about what that means. AstraZeneca did that just the other day, and they're far from the only ones in this industry (or others) spending billions to buy back their own shares while they're cutting costs elsewhere.

in the area. “Our first thoughts need to be with the families who are affected and I’ve already been talking to AstraZeneca who have assured me there will be proper support available to review career options and relocation opportunities. I’ve also spoken to

for drugs and the weak European economies are a drag on growth. Oakley writes that while both of those two effects cost AstraZeneca $3 billion in lost 2011 sales, GSK’s loss was roughly $500 million. But more than the sales of existing drug products, Oakley